跳到正文
原文
MedTech Dive 器械媒体· Susan Kelly·· 3 天前精选AI 评分75

Medtronic 的 Hugo 机器人获 FDA 扩展批准用于普通外科手术

Medtronic’s Hugo robot gets expanded FDA clearance in general surgery

AI 导读

Medtronic 的 Hugo 机器人获 FDA 批准用于所有上腹部普通外科手术,包括胆囊切除、胃旁路手术等,覆盖约 350 万例手术,占软组织手术的一半以上。

推荐理由

Medtronic 扩展 Hugo 机器人手术系统在全腹手术中的应用范围,提升其市场竞争力。

正文

This audio is auto-generated. Please let us know if you have feedback.

Dive Brief:

  • Medtronic said Tuesday the Food and Drug Administration has cleared the Hugo robotic system for use in general surgery procedures.
  • The clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia and small bowel resection. Two lower abdominal procedures, inguinal hernia and appendectomy, were also cleared. 
  • Medtronic said the combined procedures account for about 3.5 million annual surgeries in the U.S., or more than half of the soft tissue procedures performed each year.

Dive Insight:

Hugo received its initial FDA clearance in December for urologic procedures such as prostate removal, becoming the first large medtech company to bring a robotic soft tissue platform to the U.S. market since Intuitive launched the da Vinci system in 2000.

Johnson & Johnson soon followed Medtronic with FDA authorization in July for the Ottava system in general surgery, and last month, Stryker unveiled an agreement to distribute CMR Surgical’s Versius soft tissue robot in the U.S.

As it pushes into robotic procedures, Medtronic is looking to leverage its deep expertise in general surgery. The latest FDA clearance extends Hugo’s reach into specialties where Medtronic instruments have been used in open and laparoscopic surgery for decades, the company said. Surgeons can use Medtronic technology including the LigaSure vessel-sealing instrument in their robotic cases.

A growing number of U.S. hospitals are using the Hugo robot, Medtronic said. Globally, the company said Hugo procedure growth is running at more than two times the robotic surgery market and is on track to exceed 50,000 procedures by the end of the company’s fiscal year. General surgery is the highest growth area, surpassing urology and gynecology.

"Hugo expands choice with a practical option to help hospitals address capacity and access challenges, while giving surgical teams more flexibility to meet patients' needs across care settings," Matt Anderson, senior vice president and president of Medtronic's surgical business, said in a statement.

来源:MedTech Dive 器械媒体 · medtechdive.com